Last reviewed · How we verify

NCT03287544: ORACLE

Efficacy of a Combined Linguistic/Communication Therapy in Acute Aphasia After Stroke

Completed NA Last updated 3 January 2024
What this trial tests

NA trial testing Combined rehabilitation in Aphasia, Acquired in 19 participants. Completed in 27 December 2023.

Timeline
1 March 2018
Primary endpoint
30 June 2022
27 December 2023

Quick facts

Lead sponsorUniversity Hospital, Toulouse
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment19
Start date1 March 2018
Primary completion30 June 2022
Estimated completion27 December 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

18 and older, any sex, with Aphasia, Acquired. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Linguistic training is traditionally the gold standard for rehabilitation of aphasia after stroke and efficacy criteria count early stage, intensity as well as personalized treatment. To date, no clear evidence showed a specific effect of any therapy in the acute phase of aphasia after stroke. This study aims to compare the effect of a combined therapy (linguistic/communication) versus a linguistic therapy on communication performance in patients in the acute phase of aphasia after a first stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Aphasia, Acquired

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03287544.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing